Sheriff, Adam
Guri, Ina
Zebrowska, Paulina
Llopis-Hernandez, Virginia
Brooks, Imogen R.
Tekkela, Stavroula
Subramaniam, Kavita
Gebrezgabher, Ruta
Naso, Gaetano
Petrova, Anastasia
Balon, Katarzyna
Onoufriadis, Alexandros
Kujawa, Dorota
Kotulska, Martyna
Newby, Gregory
Łaczmański, Łukasz
Liu, David R.
McGrath, John A.
Jacków, Joanna
Funding for this research was provided by:
HHMI and US National Institutes of Health award (RM1 HG009490)
Confidence in Collaboration in Advanced Therapies Award (TS14352)
CureEB Charity (RE18567)
EB Research Partnership (RE17721)
EB Medical Research Foundation (RE17763)
Article History
Received: 1 August 2022
Accepted: 11 November 2022
First Online: 16 November 2022
Competing interests
: The authors declare competing financial interests: D.R.L. is a consultant and equity holder of Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver gene editing or genome engineering agents. Harvard University and the Broad Institute have filed patent applications on base editing technologies. There are no other competing interests.